BioCentury
PODCAST | Product Development

I Want KaNDy, plus Sputnik V & M&A amid COVID-19: a BioCentury podcast

August 18, 2020 2:56 AM UTC

Bayer’s deal with KaNDy could be a sign that companies are finally paying attention to Women’s health, a field in which biotechs have long struggled to raise venture money. On the latest edition of the BioCentury This Week podcast, BioCentury’s editors check in on the state of investing in and building Women’s health companies, and discuss the uproar over the speedy approval of Russia’s COVID-19 vaccine as well as dealmaking trends in biopharma.  

Editor in Chief Simone Fishburn analyzes the dynamics behind the optimism of KaNDy Therapeutics Ltd. CEO Mary Kerr, who told BioCentury’s Elizabeth Eaton last week that she is encouraged that pharma companies are increasingly seeing opportunities in Women’s health (see “Single-Asset KaNDy Finds $425M Exit”)...

BCIQ Company Profiles

Bayer AG

KaNDy Therapeutics Ltd.